Plain-English translation of NCT06254326 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a personalized immunotherapy approach for adults whose oligodendroglioma (a type of brain tumor) has come back or is getting worse. The treatment uses your own immune cells — specifically dendritic cells and T cells — that are trained in the laboratory to recognize and attack your tumor. You'll receive a combination of vaccine injections, chemotherapy with an IDH inhibitor, and infusions of these specially prepared cells over about 7 to 9 months.
Standard treatments for recurring oligodendroglioma have limited success, and many patients need better options. This trial is exploring whether teaching your own immune system to target your specific tumor might offer a new way to fight the disease and improve outcomes.
You likely qualify if…
You likely don't qualify if…
You will have surgery or a biopsy to confirm your diagnosis and collect tumor tissue. Over the next 7 to 9 months, you'll receive chemotherapy, multiple vaccine injections under the skin (starting with three injections, then monthly doses), and two intravenous infusions of your specially grown immune cells. The trial involves several hospital visits for blood collections, cell processing, and monitoring, with the most intensive phase occurring in the first few months.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States